Background:The establishment of safe and functional intravenous lines is of fundamental importance in premature sick neonates. Due to technical difficulties and various potential complications, central venous catheterization(CVC) has become an important part of long term care for prematurity. In terms of safety, it is believed by some that the central vein catheter tip should not be in the right atrium to avoid fatal complications. However, catheter performance and durability can be improved by positioning the catheter tip within the right atrium. Here, we evaluated the effectiveness of intraatrial catheter tip positioning for prematurities, to resolve this controversy between patient safety and catheter performance.Methods: Premature neonates in whom CVC had been attempted at a nursery and pediatric intensive care unit were enrolled in this study. We successfully performed eighteen CVCs in twenty patients from September 2003 to December 2004. CVC tips were in positioned within the right atrium, and central venous route, central venous catheter depth, duration of catheterization, and any complications during or after catheterization were evaluated.Results: Eighteen CVC were successful among twenty attempted in premature neonates. Two attempts failed due to guidewire insertion failure. A left supraclavicular venous approach was selected for 16 patients and a right approach for two. For intraatrial tip positioning, distances from skin to catheter tip were adjusted to an average depth of 5 cm in 11 patients and 6 cm in three patients. Two arterial punctures were the only minor complications. Mean duration of catheterization was 19 days without any long term complicaions.Conclusions: To prematue long term CVC performance, left supraclavicular subclavian vein catheterization and intraatrial catheter tip positioning should be considered a first option in premature neonates.
Background: Patients with ischemic heart disease are frequently maintained on a regimen of aspirin because of its ability to reduce variable thrombotic complications. However, aspirin has been recognized as a causative factor of increased perioperative bleeding. This study was aimed to determine whether aprotinin maintain its efficacy at reducing blood loss in patients on aspirin undergoing off-pump coronary artery bypass grafting (OPCAB).Methods: In the prospective, double blind, randomized study, we investigated 30 patients on preoperative aspirin medication undergoing OPCAB surgery. Patients received aprotinin (1 × 10 6 KIU bolus for loading plus 0.5 × 10 6 KIU/hr, n = 15, the aprotinin group) or saline solution (n = 15, the control group). Operation time, total transfusion amount during operation, and plasma D-dimer levels immediately after the induction of anesthesia and immediately after operation were investigated and compared between and within groups where possible.Results: Both group showed no comparable demographic and operation data such as operation time and number of grafts. The aprotinin group showed significantly less transfusion amount than the control group (packed RBC 352.7 ± 89.2 ml vs 478.0 ± 132.1 ml). Compared with that immediately after anesthetic induction value, postoperative D-dimer significantly increased in the control group but not in the aprotinin group. Conclusions:The above results suggest that aprotinin significantly reduces transfusion amount and probably inhibits fibrinolysis in patients with aspirin undergoing OPCAB.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.